Artelo's [MarketWatch]
Artelo Biosciences, Inc. (ARTL)
US:NASDAQ Investor Relations:
artelobio.com/investors
Company Research
Source: MarketWatch
Artelo's Shares of Artelo Biosciences Inc. ARTL, +46.28% shot up 44% in very active trading Monday, after the biopharmaceutical company announced that the National Cancer Institute awarded a $4.2 million grant to advance its cancer-treatment program. Trading volume swelled to 8.3 million shares, compared with the full-day average of about 78,200 shares. Artelo, which is focused on developing therapeutics that modulate the endocannabinoid system, said the 5-year grant is intended to support research at Stony Brook University, in collaboration with Artelo and Cold Spring Harbor Laboratory, for the development of its fatty acid binding protein 5 (FABP5) inhibitor platform. "Modulating lipid signaling has the potential to be the next revolution in cancer therapeutics," said Artelo Chief Executive Gregory Gorgas. "We believe this grant is significant validation of our platform and supports the next steps in our collaborative efforts to develop FABP5 inhibitors as potential treatments fo
Show less
Read more
Impact Snapshot
Event Time:
ARTL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARTL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARTL alerts
High impacting Artelo Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
ARTL
News
- Artelo Biosciences to Present Key Data on Three Development Programs at the 7th Cannabinoid Drug Development Summit [Yahoo! Finance]Yahoo! Finance
- Artelo Biosciences to Present Key Data on Three Development Programs at the 7th Cannabinoid Drug Development Summit GlobeNewswire
- Artelo Biosciences Announces Promising New Data on Novel Non-Opioid Treatment Approach for Osteoarthritis Pain at the 13th Annual Musculoskeletal Repair and Regeneration SymposiumGlobeNewswire
- Artelo Biosciences, Inc. (NASDAQ: ARTL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.MarketBeat
- Artelo Biosciences Reports Third Quarter 2024 Financial Results and Provides Business UpdateGlobeNewswire
ARTL
Analyst Actions
- 11/13/24 - HC Wainwright
ARTL
Sec Filings
- 11/12/24 - Form 10-Q
- 11/8/24 - Form DEF
- 11/8/24 - Form DEFA14A
- ARTL's page on the SEC website